R
Rob Carter
Researcher at Deakin University
Publications - 222
Citations - 9184
Rob Carter is an academic researcher from Deakin University. The author has contributed to research in topics: Cost effectiveness & Population. The author has an hindex of 46, co-authored 212 publications receiving 8204 citations. Previous affiliations of Rob Carter include Australian Institute of Health and Welfare & Monash University.
Papers
More filters
Journal ArticleDOI
Changing the future of obesity: science, policy, and action
Steven L. Gortmaker,Boyd Swinburn,David T. Levy,Rob Carter,Patricia L. Mabry,Diane T. Finegood,Terry T.-K. Huang,Tim Marsh,M. Moodie +8 more
TL;DR: It is called for a sustained worldwide effort to monitor, prevent, and control obesity and identifies several cost-effective policies that governments should prioritise for implementation.
Journal ArticleDOI
Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study
John Yaxley,G. Coughlin,Suzanne K. Chambers,Stefano Occhipinti,Hema Samaratunga,Hema Samaratunga,Leah Zajdlewicz,Nigel Dunglison,Rob Carter,Scott Williams,Diane Payton,Joanna Perry-Keene,Martin F. Lavin,Robert A. Gardiner,Robert A. Gardiner,Robert A. Gardiner +15 more
TL;DR: The trial was powered to assess health-related and domain-specific quality of life outcomes over 24 months and oncological outcome (positive surgical margin status and biochemical and imaging evidence of progression at 24 months).
Journal ArticleDOI
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.
Calvin J. Kuo,Filip Farnebo,Evan Y. Yu,Rolf Christofferson,Rebecca A. Swearingen,Rob Carter,Horst A. von Recum,Jenny Yuan,Junne Kamihara,Evelyn Flynn,Robert J. D'Amato,Judah Folkman,Richard C. Mulligan +12 more
TL;DR: The need for comparative analyses of different therapeutic approaches that target tumor angiogenesis is underscored and a rationale for the selection of specific antiangiogenic gene products as lead candidates for use in gene therapy approaches aimed at the treatment of malignant and ocular disorders is provided.
Journal ArticleDOI
Cost of stroke in Australia from a societal perspective. Results from the North East Melbourne Stroke Incidence Study (NEMESIS)
Helen M Dewey,Amanda G. Thrift,Cathy Mihalopoulos,Rob Carter,Richard A L Macdonell,John J McNeil,Geoffrey A. Donnan +6 more
TL;DR: Hospital and nursing home costs contributed most to the total cost of stroke (excluding SAH) in Australia for 1997, and investigation of the cost-effectiveness of rehabilitation services should become a priority in this community.
Journal ArticleDOI
Informal Care for Stroke Survivors Results From the North East Melbourne Stroke Incidence Study (NEMESIS)
Helen M Dewey,Amanda G. Thrift,Cathy Mihalopoulos,Rob Carter,Richard A L Macdonell,John J McNeil,Geoffrey A. Donnan +6 more
TL;DR: Informal care for stroke survivors represents a significant hidden cost to Australian society and because the community is rapidly aging, this informal care burden may increase significantly in the future.